Fortis Healthcare LTD

Fortis Healthcare Ltd (FORTIS) is a mid-cap Healthcare company valued at ₹55,603 crore operating in Hospital on the NSE and BSE.

Recent price move

Fortis Healthcare Ltd last traded at ₹736.5, modestly down 1.31% on the day.

Recent developments

On 2026-09-29, the Supreme Court limited the scope of Fortis Healthcare's forensic audit, restricting it to transactions involving the company, its holding company, judgment debtors, and concerned banks. On 2026-09-28, the Supreme Court allowed the forensic audit to proceed, focusing on Fortis Healthcare shares. On 2026-09-22, InGovern warned that the forensic audit order could expose listed companies to enforcement proceedings over promoters' personal debt cases. On 2026-08-28, IHH Healthcare reiterated plans to increase its stake in Fortis Healthcare, with promoter entities holding 31.17% and public shareholders holding 69%.

Financial performance

The company's business is improving, with annual revenue rising 17.3% and net profit growing 31.5% year-over-year. The latest quarter saw revenue increase 17.4% compared to the same quarter a year earlier, though net profit grew only 2.2% in the same period. Margins have improved, with the net profit margin rising 1.3 percentage points to 11.7%, while return on equity and return on capital employed remain stable at 10.5% and 12.6%, respectively.

Valuation multiples

The stock trades at 53.4 times earnings, a premium to the Healthcare median of 32.0, 6.88 times book value. It yields 0.1%.

Things to watch

The stock is 28.8% below its 52-week high, and the company faces regulatory scrutiny with the forensic audit proceeding. Promoter holding remains at 31.17%, while foreign institutional holding decreased by 0.77 percentage points in the quarter. The company's debt to equity ratio is 0.35, which is relatively low but could be a concern if leverage increases.

Where it stands

Fortis Healthcare has shown strong revenue and profit growth over the past year, with the latest quarter reflecting continued expansion. The company's net profit margin has improved, and its return metrics remain stable. However, the stock is trading below its 52-week high, and the ongoing forensic audit introduces regulatory uncertainty. The most significant figure is the stock's distance below its 52-week high at 28.8%.

Summarised by DocStoX's model on 2026-10-10 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.